SecBot SecBot
6-K ·Filed Sep 14, 2026

BNTX

BioNTech SE
BULLISH
Impact 7/10
Horizonweeks Processed2mo ago SEC0001776985-26-000063
Notable filing: 6-K
Actionable Insight ▲ Bullish

The nearly doubled median OS is a strong efficacy signal for gotistobart in a difficult-to-treat indication with limited options. However, this is non-pivotal stage 1 data with a small sample (n=87). Monitor for pivotal stage 2 results and potential regulatory filing updates. The stock may react positively on the data readout, but the binary risk of stage 2 confirmation remains.

DirectionBullish
Confidencemedium
Horizonweeks

gotistobart

● Neutral Named in this 6-K
Impact
Phase
Phase 3
Time to market
At least 2-4 years away from potential approval, assuming positive Phase 3 data leads to regulatory filing. The PRESERVE-003 Phase 3 trial is ongoing with updated OS data due Sept 2026, but no regulatory submission has been announced.
Next catalyst
None dated

What to watchThe key near-term catalyst is the WCLC 2026 conference (Sept 12-15, 2026), where updated overall survival data from the Phase 3 PRESERVE-003 trial of gotistobart in squamous NSCLC will be presented. Positive data could drive BNTX shares higher, but gotistobart is one of several late-stage assets in BioNTech's broad pipeline, so the stock impact is unlikely to be binary.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$98.86
T+0 close · Sep 14, 2026 · via day close
Latest settled
−3.05%
T+20 · $95.84 · next T+60 in 22d
Vs SPY
−5.32%
α at T+20
Latest observation
−9.98%
T+44 · FF3 residual α
  1. T+0 · Sep 14 $98.86entry
  2. T+1 · 2mo ago −2.19%α −1.74% · $96.69
  3. T+5 · 8w ago −0.87%α −0.98% · $98.00
  4. T+20 · 5w ago −3.05%α −5.32% · $95.84
  5. T+45 · todayOpen
  6. T+60 · in 22d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BioNTech and OncoC4 reported updated Phase 3 data for gotistobart in squamous NSCLC, showing median overall survival of 18.5 months vs 10.0 months for chemotherapy (HR 0.56, p=0.0295), nearly doubling survival. The data from stage 1 of the PRESERVE-003 trial is statistically significant but from a non-pivotal stage with only 87 patients, and the pivotal stage 2 is still ongoing. This is a meaningful clinical data update for a pipeline asset, but no revenue or earnings figures are reported, and the filing does not change the company's financial outlook.

Key Facts

  • Gotistobart demonstrated median OS of 18.5 months vs 10.0 months for docetaxel (HR 0.56, nominal p=0.0295) in stage 1 of PRESERVE-003 Phase 3 trial
  • Data cut-off July 17, 2026 with median follow-up of 25.4 months; 87 patients randomized (45 gotistobart, 42 docetaxel)
  • Grade 3 treatment-related AEs: 44.4% gotistobart vs 48.8% docetaxel; safety profile manageable
  • Pivotal stage 2 of PRESERVE-003 is ongoing at more than 160 sites globally
  • Gotistobart received FDA Fast Track Designation (2022), Orphan Drug Designation (2025), and China NMPA Breakthrough Therapy Designation (2025)

Financial Impact

No financial figures reported; clinical data update only

Risk Factors

  • Stage 1 data is non-pivotal with only 87 patients; pivotal stage 2 results could differ
  • Competition from other CTLA-4 and immunotherapy approaches in NSCLC
  • Regulatory approval is not guaranteed; requires confirmation in larger pivotal trial

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
78% bullish (27 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001776985-26-000063
Document: form6-kwclcgotistobart14se.htm0001776985-26-000063
Document: 0001776985-26-000063-index-headers.html0001776985-26-000063
Document: 0001776985-26-000063-index.html0001776985-26-000063
Document: 0001776985-26-000063.txt0001776985-26-000063

Track record

38 reports on BNTX

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +25.10% at T+20 after the Mar 24, 2026 report. 11 of 15 went positive at some point.

Filters
  1. Nov 10, 20266d ago 6-K Neutral 4/10 Entry $87.21 Now $85.26 −2.24% settles Feb 8
  2. Nov 3, 202613d ago 6-K Neutral 5/10 No price data
  3. Nov 3, 202613d ago 6-K Neutral 5/10 No price data
  4. Nov 3, 202613d ago Press Release Neutral 5/10 Entry $86.92 Now $85.26 −1.91% settles Feb 1
  5. Oct 29, 202618d ago Institutional Cluster Mixed 3/10 Entry $89.13 Now $85.26 −4.34% settles Jan 27
  6. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $86.86 Now $85.26 −1.84% settles Jan 22
  7. Oct 26, 202621d ago 6-K Bearish 5/10 Entry $86.86 Now $85.26 +1.84% settles Jan 22
  8. Oct 26, 202621d ago Press Release Bearish 6/10 Entry $86.86 Now $85.26 +1.84% settles Jan 22
  9. Oct 25, 202622d ago Press Release Bullish 6/10 Entry $86.86 Now $85.26 −1.84% settles Jan 22
  10. Oct 22, 202625d ago 6-K Neutral 5/10 Entry $89.67 Now $85.26 −4.92% settles Jan 20
Showing 10 of 38

US Market Status

Market Closed · Opens Tue (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 14, 2026